Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction is a research paper published in New England Journal of Medicine (2019). On theSindex it has a DataRank of 1.3. It has been cited 5,622 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.3
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Additional file 1 of Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
Additional file 1 of Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
Additional file 2 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
Additional file 2 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
Additional file 1 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 1 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 2 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 2 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 1 of Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Additional file 1 of Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Additional file 1 of Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Additional file 1 of Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Additional file 1 of The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
Additional file 1 of The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
Additional file 1 of Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Additional file 1 of Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Additional file 1 of Association of treatments for acute myocardial infarction and survival for seven common comorbidity states: a nationwide cohort study
Additional file 1 of Association of treatments for acute myocardial infarction and survival for seven common comorbidity states: a nationwide cohort study